NDAORALTABLET
Approved
Apr 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ESTROVIS (quinestrol) is an oral estrogen tablet approved by Pfizer in 1996 for hormone replacement therapy and related estrogen-deficiency indications. Quinestrol is a synthetic estrogen that binds to estrogen receptors to replace deficient endogenous hormone levels in postmenopausal women and other patient populations with estrogen deficiency.
LOE Approaching
As LOE approaches, the brand team is likely transitioning to defend market share against generic competition and may be downsizing, limiting expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ESTROVIS offers minimal career growth given its LOE-approaching status and zero linked job opportunities. Professionals joining this product are likely managing decline rather than driving expansion.
Brand ManagerField Sales Representative
Worked on ESTROVIS at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.